Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25280473 | 0.77 | HTR2A (0.63) | HTR2A | |
| SCHEMBL20232078 | 0.71 | TAAR1 (0.48) | CYP3A4PKM | |
| SCHEMBL16428954 | 0.71 | SMN1; SMN2 (0.44) | SMN1; SMN2HTR2AKMT2A | |
| SCHEMBL18159270 | 0.69 | MAPT (0.38) | SMN1; SMN2KMT2AMEN1CYP3A4PKM | |
| SCHEMBL7175921 | 0.68 | PLAAT3 (0.54) | SLC2A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18829988 | 0.67 | GAA (0.49) | KMT2AMEN1CYP3A4LMNA | |
| SCHEMBL18159078 | 0.67 | MTNR1A (0.41) | CYP2C9CYP2C19 | |
| SCHEMBL23048383 | 0.66 | PDE3B (0.50) | SMN1; SMN2CYP3A4 | |
| SCHEMBL15797275 | 0.64 | KDM4E (0.66) | KMT2AHTTLMNA | |
| SCHEMBL8080817 | 0.63 | L3MBTL1 (0.56) | KMT2AMEN1CYP3A4HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | CD274 2241/4885SLC2A1 4487/4885SMN1; SMN2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.